Phase 3 Atrial Fibrillation Trial, Recruiting (NCT06722196)

Phase 3 Atrial Fibrillation Trial, Recruiting NCT06722196 Sponsor: Jilin Heart Hospital Condition: Atrial Fibrillation

Printed from Voxsanity (voxsanity.com.au) — NCT06722196 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Atrial Fibrillation

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are scheduled for planned (non-emergency) heart surgery through a full chest opening (sternotomy)
Your surgery is for one or more of the following conditions: blocked heart arteries, aortic valve problems, mitral valve problems, tricuspid valve problems, or disease of the main artery leaving the heart (ascending aorta)

Who may not be able to join:

You have a history of any irregular heart rhythm (such as atrial fibrillation or other arrhythmias), regardless of how long it lasted
You are having this heart surgery for a second time (reoperation)
Your surgery is needed urgently due to a heart attack or severe heart failure (cardiogenic shock)
You have a thyroid condition of any kind
You have a condition called hypertrophic obstructive cardiomyopathy (HOCM), which is a thickening of the heart muscle that blocks blood flow (confirm with trial site)
You have a pacemaker or an implanted heart defibrillator (ICD)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 20 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Massimo G Lemma, PhD, Jilin Heart Hospital

Phone: +86 13630550809

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06722196

Sponsor: Jilin Heart Hospital

Phase: Phase 3

Status: Recruiting

Condition: Atrial Fibrillation

Trial contact: +86 13630550809

More information: https://clinicaltrials.gov/study/NCT06722196

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are scheduled for planned (non-emergency) heart surgery through a full chest opening (sternotomy)
Your surgery is for one or more of the following conditions: blocked heart arteries, aortic valve problems, mitral valve problems, tricuspid valve problems, or disease of the main artery leaving the heart (ascending aorta)

Who may not be able to join:

You have a history of any irregular heart rhythm (such as atrial fibrillation or other arrhythmias), regardless of how long it lasted
You are having this heart surgery for a second time (reoperation)
Your surgery is needed urgently due to a heart attack or severe heart failure (cardiogenic shock)
You have a thyroid condition of any kind
You have a condition called hypertrophic obstructive cardiomyopathy (HOCM), which is a thickening of the heart muscle that blocks blood flow (confirm with trial site)
You have a pacemaker or an implanted heart defibrillator (ICD)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 20 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Jilin Heart Hospital

Registry

ClinicalTrials.gov

Start date

15 February 2025

Est. completion

15 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

postoperative atrial fibrillation versus control

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov